In vivo testing of 177Lu-labelled anti-PSMA antibody as a new radioimmunotherapeutic agent against prostate cancer.

Authors :: Behe M
Alt K
Deininger F
Bühler P
Wetterauer U
Weber WA
Elsässer-Beile U
Wolf P
Source :: In vivo (Athens, Greece) [In Vivo] 2011 Jan-Feb; Vol. 25 (1), pp. 55-9.
Publication Year :: 2011
Abstract: Aim: The goal of the present study was to test the (177)Lu-labelled anti-PSMA monoclonal antibody 3/F11 ((177)Lu-DOTA-3/F11) as a new radioimmunotherapeutic agent in a prostate cancer SCID mouse xenograft model.<br />Materials and Methods: The mAb 3/F11 was (177)Lu labelled using 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) as chelating agent. DOTA-3/F11 was tested for cell binding and serum immunoreactivity by flow cytometry. The biodistribution and the therapeutic efficacy of (177)Lu-DOTA-3/F11 in mice bearing PSMA-positive C4-2 prostate cancer xenografts were evaluated.<br />Results: 3/F11 and DOTA-3/F11 showed high and specific cell binding and similar serum half-lives of approximately seven days. Biodistribution studies revealed an increasing tumour uptake of (177)Lu DOTA-3/F11 over time with maximum tumour-to-muscle and tumour-to-blood ratios after 72 h. A single dose of 1 MBq (177)Lu-DOTA-3/F11 inhibited tumour growth and prolonged survival.<br />Conclusion: This study indicated that (177)Lu-DOTA-3/F11 may be a suitable radioimmunotherapeutic agent for the treatment of prostate cancer.

Subjects :: Animals
Cell Line, Tumor
Humans
Isotope Labeling
Male
Mice
Mice, SCID
Radioisotopes
Xenograft Model Antitumor Assays
Antibodies, Monoclonal therapeutic use
Antigens, Surface immunology
Coordination Complexes therapeutic use
Glutamate Carboxypeptidase II immunology
Lutetium therapeutic use
Prostatic Neoplasms radiotherapy
Radioimmunotherapy methods

Tools